Last reviewed · How we verify

metronidazole, clindamycin, or piperacillin-tazobactam

Michael Cohen-Wolkowiez · Phase 2 active Small molecule

metronidazole, clindamycin, or piperacillin-tazobactam is a Small molecule drug developed by Michael Cohen-Wolkowiez. It is currently in Phase 2 development.

At a glance

Generic namemetronidazole, clindamycin, or piperacillin-tazobactam
SponsorMichael Cohen-Wolkowiez
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about metronidazole, clindamycin, or piperacillin-tazobactam

What is metronidazole, clindamycin, or piperacillin-tazobactam?

metronidazole, clindamycin, or piperacillin-tazobactam is a Small molecule drug developed by Michael Cohen-Wolkowiez.

Who makes metronidazole, clindamycin, or piperacillin-tazobactam?

metronidazole, clindamycin, or piperacillin-tazobactam is developed by Michael Cohen-Wolkowiez (see full Michael Cohen-Wolkowiez pipeline at /company/michael-cohen-wolkowiez).

What development phase is metronidazole, clindamycin, or piperacillin-tazobactam in?

metronidazole, clindamycin, or piperacillin-tazobactam is in Phase 2.

Related